Abstract
PurposeThere are controversial debates if patients with Hürthle cell carcinoma, also known as oxyphilic or oncocytic cell follicular thyroid carcinoma, have a poorer outcome. In this study, we systematically evaluated the clinical outcome in a large patient cohort following thyroidectomy and initial I-131 radioactive iodine therapy (RIT).MethodsWe retrospectively evaluated a total of 378 patients with diagnosed oncocytic follicular Hürthle cell carcinoma (OFTC) (N = 126) or with classical follicular thyroid carcinoma (FTC) (N = 252). Patients received thyroidectomy and complementary I-131 RIT. Clinical data regarding basic demographic characteristics, tumor grade, persistent disease and recurrence during follow-up, and disease-free, disease-specific, and overall survival were collected during follow-up of 6.9 years (interquartile range 3.7; 11.7 years). Univariate and multivariate analyses were used to identify factors associated with disease-related and overall survival.ResultsBefore and after matching for risk factors, recurrence was significantly more frequently diagnosed in OFTC patients during follow-up (17% vs. 8%; p value 0.037). Likewise, OFTC patients presented with a reduced mean disease-free survival of 17.9 years (95% CI 16.0–19.8) vs. 20.1 years (95% CI 19.0–21.1) in FTC patients (p value 0.027). Multivariate analysis revealed OFTC (HR 0.502; 95% CI 0.309–0.816) as the only independent prognostic factor for disease-free survival. Distant metastases of OFTC patients were significantly less iodine-avid (p value 0.014). Mean disease-specific and overall survival did not differ significantly (p value 0.671 and 0.687) during follow-up of median 6.9 years (3.7; 11.7 years).ConclusionsOur study suggests that recurrence is more often seen in OFTC patients. OFTC patients have a poorer prognosis for disease-free survival. Thus, OFTC and FTC behave differently and should be categorized separately. However, patients suffering from OFTC present with the same overall and disease-specific survival at the end of follow-up indifferent to FTC patients after initial RIT.
Highlights
The incidence of thyroid cancer has increased globally [1]
Only patients diagnosed with oncocytic variant of follicular carcinoma (OFTC) and classical Follicular thyroid carcinoma (FTC) with total or near total thyroidectomy followed by complementary initial radioiodine therapy were selected
Thirty-three percent presented with oncocytic follicular Hürthle cell carcinoma (OFTC) (N = 126) and 67% with FTC (N = 252)
Summary
The incidence of thyroid cancer has increased globally [1]. Follicular thyroid carcinoma (FTC) is the second most common epithelial-derived thyroid cancer histotype after papillary carcinoma (PTC) [1, 2]. The incidence of FTC varies in different regions worldwide most likely depending on the iodine supply [3, 4]. Hürthle cell carcinoma (OFTC), known as oxyphilic or oncocytic cell follicular thyroid carcinoma, represents about 3–5% of thyroid carcinomas [5,6,7,8]. OFTC has been considered as a variant of follicular thyroid cancer [9].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.